key: cord-0821058-7z3oj6nv authors: Eger, Katrien; Bel, Elisabeth H. title: Asthma and COVID-19: do we finally have answers? date: 2020-12-30 journal: Eur Respir J DOI: 10.1183/13993003.04451-2020 sha: 820c1df98c057811b66ffdf0520dad743279a2a7 doc_id: 821058 cord_uid: 7z3oj6nv These large-scale studies confirm previous findings about a slightly increased incidence of COVID-19, but not of severe COVID-19, in asthma patients. Still, no definitive conclusions can be drawn since many bias factors have not been taken into account. The 2019 coronavirus disease pandemic has already claimed the lives of nearly 1.5 million people and the virus is continuing to spread across the world. [1] The disease can affect anyone, and although SARS-CoV-2 infection leads to mild COVID-19 in the majority of cases, the proportion of patients developing severe pneumonia is of great concern. It is now well-recognized that older age, obesity, cardiovascular disease and diabetes are risk factors of poor COVID-19 outcome. [2] [3] [4] What is not yet clear is whether chronic respiratory diseases like asthma are amongst the risk factors as well. The many studies that have addressed this question show discrepant results and point towards numerous factors that may play a role in the susceptibility and severity of COVID 19 in asthma patients. [5] [6] [7] [8] [9] [10] These include the severity of asthma itself, the asthma phenotype (allergic or non-allergic), asthma medication (corticosteroids or no corticosteroids), and comorbidities. [11] [12] [13] [14] [15] Because of this complex interplay between numerous factors involved, there is a need for large-scale studies that allow adjustment for confounders, making it possible to evaluate the true impact of asthma on the susceptibility and outcome of COVID-19. analysed a large number of patients on biologic therapy (n=865), and found a relatively high incidence of COVID-19 of 2.3% in these patients, while this was 1.4% in the general asthma population. Only two out of 20 infected patients on asthma biologics (10%) were hospitalized. While these numbers are small, they are consistent with other reports suggesting that there is no increased risk of a poor outcome in asthma patients on biologics. [21, 26] In summary, these large-scale studies have confirmed previous findings about the risk for asthma patients to develop (severe) COVID-19. Asthma patients appear to be slightly more susceptible to contracting COVID-19, but severe disease progression does not seem to be related to medication use, including asthma biologics, but rather to older age and co-morbidities. However, no definitive conclusions can be drawn yet as many factors can influence the reported incidences of (severe) COVID-19 (Figure 1 ). These potential bias factors have not been taken into account in the published studies so far and therefore many questions remain unanswered. Similar large-scale, preferably multinational real-life studies with detailed information on asthma phenotype and medication usage in patients with a confirmed diagnosis of COVID-19 would be an ideal next step to further build on this new evidence. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory Association between asthma and clinical mortality/morbidity in COVID-19 patients using clinical epidemiologic data from Korean Disease Control & Prevention. Allergy Association of asthma and its genetic predisposition with the risk of severe COVID-19 COVID-19 Susceptibility in Bronchial Asthma Asthma prolongs intubation in COVID-19 The Impact of Asthma on Mortality in Patients With COVID-19 Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19 Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform COVID-19 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype Effect of Asthma and Asthma Medication on the Prognosis of Patients with COVID-19 The Impact of COVID-19 on Patients with Asthma Asthma among hospitalized patients with COVID-19 and related outcomes Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19 Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19 Early View COVID-19 and biologics in severe asthma : data from the Belgian Severe Asthma Registry COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study Inhaled corticosteroids and COVID-19: A systematic review and clinical perspective Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2 Allergy 2020 Is asthma protective against COVID-19. Allergy. 2020. Online ahead of print COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments